Cardax Inc · OTC:CDXI
Cardax — Investor Presentation (February 2014)
32 slides from Cardax's investor presentation, Feb 12, 2014
Slide 1: Corporate Presentation Updated February 2014
Corporate Presentation Updated February 2014
Slide 2: Forward-Looking Statement Disclaimer
2 There are statements in this presentation that are not historical facts . These “forward - looking statements” can be identified by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,” “strategy,” “
Slide 3: Cardax: Focusing on the Source of Inflammation
3 Cardax: Focusing on the Source of Inflammation TM Cardax is developing astaxanthin therapies for large unmet medical needs where inflammation and oxidative stress play key causative roles. CARDAX IN BRIEF ▪ Cardax is focusing first on developing products utilizing astaxanthin, a naturally occurrin
Slide 4: About Cardax
4 About Cardax Cardax oral anti - inflammatory products address underserved multi - billion dollar chronic disease markets. CORPORATE HIGHLIGHTS ▪ Cardax believes that the manufacturing advantages brought about by the JDSA will provide an efficient, scalable, and economical path to mass markets not
Slide 5: Inflammation and Disease
5 Inflammation and Disease Cardax’s pharmaceutical development program will target conditions where inflammation and oxidative stress are strongly implicated. CONDITIONS TARGETED ▪ Osteoarthritis ▪ Cognitive Decline ▪ Metabolic Syndrome ▪ Liver Disease (NASH, ASH) ▪ Cardiovascular Disease (Atheroscl
Slide 6: Inflammation and Disease Cont.
6 Inflammation and Disease Cont. Inflammation is the body's natural response to injury, irritants, and pathogens – chronic inflammation may occur when the immune system does not function properly and increases disease risk. CHRONIC INFLAMMATION ▪ Excess oxidative stress inside cells at the mitochond
Slide 7: Astaxanthin Fights Inflammation at Its Source
7 Astaxanthin Fights Inflammation at Its Source Astaxanthin reduces the oxidative stress that initiates and perpetuates the chronic and pathological activation of a number of inflammatory pathways. MECHANISM OF ACTION ▪ Astaxanthin spans plasma, mitochondrial, and nuclear membranes of the targeted t
Slide 8: Astaxanthin in Nature
8 Astaxanthin in Nature Astaxanthin is a naturally occurring marine compound that was found to improve animal health and vitality, prompting further scientific study. ROLE OF ASTAXANTHIN IN THE MARINE FOOD CHAIN 1 3 2 Astaxanthin is synthesized by microalgae; astaxanthin is believed to protect the a
Slide 9: Astaxanthin Scientific Research
9 Astaxanthin Scientific Research 1,000+ peer reviewed papers featuring astaxanthin have been published in leading scientific journals. RESEARCH SUPPORTS USE ▪ More than 40 human clinical trials support the safety and efficacy of astaxanthin. ▪ More than 50 peer reviewed papers published by Cardax t
Slide 10: Astaxanthin Scientific Research Cont.
Astaxanthin Scientific Research Cont. Astaxanthin and Related Esters have demonstrated efficacy in models of inflammatory - mediated disease. DEMONSTRATED EFFICACY IN SCIENTIFIC RESEARCH ▪ Reduction of TNF - α levels equivalent to a steroid. ▪ Reduction of liver enzymes and liver histological damage
Slide 11: Benefits of Astaxanthin Use
Benefits of Astaxanthin Use Astaxanthin is proven to reduce inflammation at its source, without the harmful side effects of common anti - inflammatory and pain relief medications. ADVANTAGES OF ASTAXANTHIN USE * in relevant animal models. Possible Side Effects of Other Anti - Inflammatory / Pain Rel
Slide 12: Broader Awareness is Driving Astaxanthin Demand
Broader Awareness is Driving Astaxanthin Demand Consumer interest in astaxanthin has led to a sharp increase in demand; some manufacturer sales have doubled since 2010. ASTAXANTHIN SEARCH VOLUME 2004 – PRESENT Source: Google Trends astaxanthin interest over time Astaxanthin – Normalized Search Volum
Slide 13: Recent Coverage of Astaxanthin in Mainstream Media
Recent Coverage of Astaxanthin in Mainstream Media SELECT MEDIA COVERAGE All registered trademarks, logos, images, and content are property of their respective owners; there is no endorsement of Car dax or any its products or technologies by any such owner.
Slide 14: Agricultural Astaxanthin
14 Agricultural Astaxanthin Currently, astaxanthin for nutraceutical use is primarily derived from low volume agricultural ( microalgal ) sources; agricultural producers face significant challenges to meet growing global demand. CERTAIN ISSUES FACED BY AGRICULTURAL SUPPLIERS The astaxanthin nutraceu
Slide 15: Nature-Identical Synthetic Astaxanthin
15 “Nature - Identical” Synthetic Astaxanthin The Cardax - BASF JDSA will enable an efficient, scalable, and economical path to mass markets not currently available to low - volume agricultural producers. NOVEL MANUFACTURING APPROACH ▪ A proprietary and scalable manufacturing process for the efficie
Slide 16: Nature-Identical Synthetic Astaxanthin Cont.
16 “Nature - Identical” Synthetic Astaxanthin Cont. Production of “nature - identical” synthetic astaxanthin has multiple advantages over agricultural astaxanthin. SYNTHETIC VS. AGRICULTURAL PRODUCTION ▪ Synthetic production methods can be scaled to accommodate growing global demand with consistent
Slide 17: Cardax Astaxanthin: Pharmaceutical Development
17 Cardax Astaxanthin: Pharmaceutical Development Cardax intends to pursue the clinical development of astaxanthin as an over - the - counter drug and/or prescription drug. CLINICAL DEVELOPMENT PROGRAM ▪ Cardax plans to conduct three to five low - risk, low - cost, clinical trials after obtaining ad
Slide 18: Cardax Pharmaceutical Pipeline
Cardax Pharmaceutical Pipeline Cardax plans to pursue multiple indications for Cardax Astaxanthin and two other exceptionally safe, anti - inflammatory compounds from the same family, zeaxanthin and lycophyll . DISEASE STATES TARGETED ▪ Osteoarthritis ▪ Cognitive Decline ▪ Metabolic Syndrome ▪ Liver
Slide 19: Astaxanthin for Osteoarthritis
19 Astaxanthin for Osteoarthritis Cardax Astaxanthin is well positioned to meet the needs of patients suffering from osteoarthritis. OSTEOARTHRITIS OPPORTUNITY ▪ Current treatments for osteoarthritis include NSAIDs (Celebrex®, Aleve®, etc.), steroids (Prednisolone, etc.), and the nutraceutical gluco
Slide 20: Astaxanthin for Osteoarthritis Cont.
Astaxanthin for Osteoarthritis Cont. The Centers for Disease Control and Prevention report that the amount of direct medical expenditures in the U.S. for arthritis and other rheumatic conditions was $80.8B in 2003. OSTEOARTHRITIS MARKET OVERVIEW ▪ According to the Centers for Disease Control and Pre
Slide 21: Astaxanthin for Cognitive Decline
21 Astaxanthin for Cognitive Decline A human clinical trial supports the potential for Cardax Astaxanthin to improve cognitive function in an elderly population afflicted with age - related forgetfulness. COGNITIVE DECLINE OPPORTUNITY ▪ Potential treatment for an expanding population with few option
Slide 22: Astaxanthin for Metabolic Syndrome
Astaxanthin for Metabolic Syndrome Cardax Astaxanthin could lessen the majority of physiological measures defining metabolic syndrome, and thereby decrease the risk of ensuing cardiovascular disease, diabetes, and liver disease. METABOLIC SYNDROME OPPORTUNITY ▪ Metabolic syndrome is a combination of
Slide 23: Intellectual Property
23 Intellectual Property Cardax has a robust intellectual property portfolio that offers a valuable competitive advantage. PATENT PORTFOLIO ▪ Cardax patents protect compositions of matter, pharmaceutical compositions, and pharmaceutical uses of its Astaxanthin and related products in certain disease
Slide 24: Senior Management Team
24 Senior Management Team DAVID G. WATUMULL, PRESIDENT & CEO, DIRECTOR More than twenty years industry experience as a biotechnology executive, analyst, and investment banker. Co - founder of Cardax and co - inventor of Cardax’s technology. Conceived and led development of first astaxanthin dietary
Slide 25: Senior Management Team Cont.
25 Senior Management Team Cont. TIMOTHY KING, PH.D., VP RESEARCH Former Staff Scientist at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington, Dr. King has over 22 years of combined academic and private sector scientific research experience including utilizing cell culture and
Slide 26: Board of Directors
26 Board of Directors NICHOLAS MITSAKOS, EXECUTIVE CHAIRMAN Chairman and CEO of Arcadia Holdings, Inc., focusing on private equity investments globally. Arcadia’s financial partners include Trust Company of the West, a $150B investment company, and Canyon Partners, a $20B hedge fund. Mitsakos is als
Slide 27: Selected Astaxanthin Clinical Trials
Selected Astaxanthin Clinical Trials
Slide 28: Astaxanthin Reduces Inflammation in Humans
Astaxanthin Reduces Inflammation in Humans STUDY DESIGN ▪ 17 subjects at risk for metabolic syndrome (ages 22 - 65) with waist circumference (>85cm) and one of the following: ▪ Fasting plasma glucose >100mg/dL ▪ Triglyceride level >150mg/dL ▪ HDL cholesterol <40mg/dL ▪ Blood pressure >135/85mmHg ▪ 1
Slide 29: Clinical Efficacy of Astaxanthin in Metabolic Syndrome
Clinical Efficacy of Astaxanthin in Metabolic Syndrome STUDY DESIGN ▪ 61 subjects at risk for metabolic syndrome (ages 25 - 60): ▪ Fasting triglyceride level 120 - 200mg/ dL (normal to borderline high risk). ▪ Double - blind, placebo - controlled study. ▪ 12 weeks; 0, 6, 12, or 18 mg daily of astaxa
Slide 30: Clinical Efficacy of Astaxanthin in Obese Patients
Clinical Efficacy of Astaxanthin in Obese Patients STUDY DESIGN ▪ 27 obese subjects (ages 20 - 55): ▪ BMI > 25 (excluding diabetes, hypertension, cardio disease) ▪ Double - blind, placebo - controlled study. ▪ 12 weeks; 20 mg daily of astaxanthin. ▪ Measures: lipid profiles and oxidative stress. RES
Slide 31: Presentation disclaimer
31 The information contained in this Corporate Presentation (this “Presentation”) summarizes certain information about Cardax, Inc . (the “Company”) and its subsidiary Cardax Pharma , Inc . and is qualified in its entirety by, and should be considered in conjunction with, the information (the “Compa
Slide 32: Cardax, Inc. contact details
Cardax, Inc. 2800 Woodlawn Drive, Suite 129 Honolulu, Hawaii 96822 (808) 457 - 1400